[1]. Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer.
eLife [巻]10 （2021年） [査読] 有
[DOI] [2]. Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer.
Journal of cancer research and clinical oncology （2022年） [査読] 有
[DOI] [3]. MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.
NPJ precision oncology [巻]6 [号]1 [頁]88 （2022年） [査読] 有
[DOI] [4]. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy.
Cancer immunology, immunotherapy : CII （2023年） [査読] 有
[DOI] [5]. Characterization of BRAFT599dup Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling.
JCO precision oncology [巻]8 [頁]e2300538 （2024年） [査読] 有
[DOI]